UPB · Upstream Bio, Inc.

$6.39 -0.01 (-0.16%) At close · Jul 29

Market Cap

$348.29M

54.42M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
E. Rand Sutherland	CEO	$650,000	—	—	$3,300,350	$341,250	$10,500	$4,302,100
Michael Paul Gray	CFO	$490,000	—	—	$1,287,137	$205,800	$10,500	$1,993,437
Aaron Deykin	Chief Medical Officer and Head of Research and Development	$515,000	—	—	$1,089,116	$216,300	$10,500	$1,830,916

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
E. Rand Sutherland	CEO	$407,955	—	—	$8,375,648	$315,000	$10,350	$9,108,953
Michael Paul Gray	CFO	$352,667	—	—	$2,401,910	$184,000	—	$2,938,577
Allison Ambrose	General Counsel	$17,292	$42,500	—	$1,474,045	—	—	$1,533,837
Samantha Truex	CEO	$113,208	—	—	$120,381	—	$638,917	$872,507

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Samantha Truex	CEO	$475,000	—	—	$943,227	$235,125	$9,900	$1,663,252

Key facts CIK 2022626 CUSIP 91678A107 13F (30d) 15 filings 15 filers Visit website Investor relations